Antitumor Imidazotetrazines. 40. Radiosyntheses of [4-<sup>11</sup>C-<i>C</i><i>arbonyl</i>]- and [3-<i>N</i>-<sup>11</sup>C-<i>M</i><i>ethyl</i>]-8-carbamoyl-3-methylimidazo[5,1-<i>d</i>]-1,2,3,5-tetrazin-4(3<i>H</i>)-one (Temozolomide) for Positron Emission Tomography (PET) Studies
作者:Gavin D. Brown、Sajinder K. Luthra、Cathryn S. Brock、Malcolm F. G. Stevens、Patricia M. Price、Frank Brady
DOI:10.1021/jm020921f
日期:2002.12.1
[(11)C-methyl]methyl isocyanate (8) gave [3-N-(11)C-methyl]temozolomide (9) in 14-20% radiochemical yield from [(11)C-methyl]methyl isocyanate (8) (decay corrected). The position of radiolabeling in the 3-N-methyl group was confirmed by [(11/13)C]colabeling and subsequent carbon-13 NMR spectroscopy. Similarly, the reaction of 5-diazoimidazole-4-carboxamide (7) with [(11)C-carbonyl]methyl isocyanate (10) gave
8-氨基甲酰基-3-甲基咪唑并[5,1-d] -1,2,3,5-四嗪-4(3H)-1(替莫唑胺,1)是抗癌前药。作为研究以探究其使用PET假定的作用方式的研究的一部分,我们开发了两种快速放射性合成路线来制备替莫唑胺,并用短寿命的正电子发射体carbon-11标记(t(1/2)= 20.4分钟)。5-重氮咪唑-4-羧酰胺(7)与新型标记剂[(11)C-甲基]甲基异氰酸酯(8)的反应产生了[3-N-(11)C-甲基] temozolomide(9) [(11)C-甲基]甲基异氰酸酯(8)的放射化学产率为20%(已校正衰变)。通过[(11/13)C]共标记和随后的碳13 NMR光谱确认了放射性标记在3-N-甲基中的位置。同样,5-重氮咪唑-4-羧酰胺(7)与[(11)C-羰基]甲基异氰酸酯(10)的反应制得[4-(11)C-羰基]替莫唑胺(11),放射化学收率为10-15% [(11)C-羰基]